TNBCs do not express any of the three major hormone receptors (ER, PR, and HER2) found in other subtypes of breast cancer and are considered the most aggressive subtype of breast tumors due to the lack of therapeutic targets (Harbeck et al., 2019). This evidence concerns the gene ERBB2 and breast carcinoma.